Preoperative use of blood-thinning drugs is safe for cancer patients

December 15, 2015

CHICAGO (December 15, 2015): Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year.


Venous thromboembolism (VTE) is a common occurrence in cancer patients. Those undergoing major operations are at higher risk of deep vein thrombosis (DVT), a condition that occurs when blood in the vein pools, usually in the calf or thigh, and forms a clot. The consequences can be serious because the blood clot can break loose from the leg vein, travel to the lungs and block the blood vessels that supply the lungs. This complication, called a pulmonary embolism, can be fatal.


While administering blood-thinning drugs after surgical procedures has become a common practice, no large studies have investigated the safety and efficacy of giving a single preoperative dose of blood thinners, in addition to post-operative doses, to patients undergoing major cancer operations. During smaller procedures, doctors typically administer clot-preventing medication, but its blood-thinning action in the body can lead to excessive bleeding, transfusions, and other serious issues.


Upon analyzing the American College of Surgeons National Surgical Quality Improvement Project (ACS NSQIP®) database, the research team discovered that their institution had higher than expected rates of DVT and pulmonary embolism. NSQIP is the leading nationally validated, risk-adjusted, outcomes-based program to measure and improve the quality of surgical care in hospitals, and was the tool that prompted the researchers to set up the trial and work on this important quality improvement parameter. At the request of Peter T. Scardino, MD, FACS, chairman of surgery at Memorial Sloan Kettering Cancer Center (MSKCC), New York City, the research team set out to identify the reason for their VTE rate and to lower it.


"We weren't sure if our VTE rate was due to the complexity of our operations, the fact that our patients had cancer, or that we weren't administering heparin, which could decrease the blood clots," said study coauthor Vivian Strong, MD, FACS, an associate attending surgeon and NSQIP surgical champion at MSKCC.


"There was serious concern that administering preoperative VTE prophylaxis to our patients, who undergo extensive surgical resection, would increase the risk of bleeding. Knowing, from NSQIP, that we had a higher than expected VTE rate, the question was whether it was safe to expose our patients to the additional bleeding risk from VTE prophylaxis," added lead study author Luke V. Selby, MD, the department of surgery's outcomes research fellow.


For this study, Dr. Selby and colleagues selected 2,058 patients undergoing major operations for cancer at MSKCC to receive preoperative VTE prophylaxis (low-molecular-weight heparin or unfractionated heparin). The investigators then compared bleeding, transfusion, and VTE rates from that cohort of cancer patients with a group of 4,960 cancer patients who had already undergone a major surgical procedure a year earlier, but did not receive preoperative VTE prophylaxis.


The study findings showed that providing one dose of anticoagulant medicines before surgery is safe in cancer patients undergoing major operations. Patients who had received preoperative VTE prophylaxis had lower transfusion rates (17 percent versus 14 percent) without a difference in major bleeding. In addition, rates of deep vein thrombosis and pulmonary embolism were significantly lower in the VTE prophylaxis group (1.3 percent versus 0.2 percent; and 1.0 percent versus 0.4 percent, respectively).


Because of the findings from this study, Memorial Sloan Kettering Cancer Center has adopted a routine anticoagulation approach for patients who meet certain selection criteria. "This research has been a practice-changing study for our institution," Dr. Strong said. "Our study results demonstrate to other institutions that you can use preoperative VTE prophylaxis safely, so I think that it has very broad-reaching, practice-changing implications."
-end-
Other study participants include Mindy Sovel, MPH; Daniel D Sjoberg, MA; Margaret McSweeney, NP; Damon Douglas, PharmD; David R Jones, MD, FACS; Peter T Scardino, MD, FACS; Gerald A Soff, MD; Nicola Fabbri, MD; Kent Sepkowitz, MD; Inderpal S Sarkaria, MD, FACS; and the MSKCC VTE Task Force.


"FACS" designates that a surgeon is a Fellow of the American College of Surgeons.


The study was supported in part by NIH Core Grant # P30 CA 008748.


Citation: Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism, Selby, Luke V. et al., Journal of the American College of Surgeons.


About the American College of Surgeons

The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 80,000 members and is the largest organization of surgeons in the world. For more information, visit http://www.facs.org.

American College of Surgeons

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.